Dr. Jane Yanagawa's ultimate goal as a physician-scientist is to improve long-term outcomes in patients with early-stage resectable non-small cell lung cancer. She hopes to develop a scientific portfolio in translational lung cancer research focusing on mechanisms of immune-modulation that ultimately extends to clinical trials of immunotherapies for patients with resectable lung cancer.
Efficace F, Fayers P, Pusic A, Cemal Y, Yanagawa J, Jacobs M, la Sala A, Cafaro V, Whale K, Rees J, Blazeby J; European Organization for Research and Treatment of Cancer Quality-of-Life Group (Patient-Reported Outcome Measurements Over Time in Oncology Registry). Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials. Cancer. 2015 Sep 15;121(18):3335-42. doi: 10.1002/cncr.29489. Epub 2015 Jun 16.
Lee MH, Kachroo P, Pagano PC, Yanagawa J, Wang G, Walser TC, Krysan K, Sharma S, John MS, Dubinett SM, Lee JM. Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway. J Cancer Sci Ther. 2014 Nov;6(11):468-477. Epub 2014 Nov 15.
Lin AY, Kotova S, Yanagawa J, Elbuluk O, Wang G, Kar N, Elashoff D, Grogan T, Cameron RB, Singh A, Chmielowski B, Federman N, Nelson SD, Lee P, Eilber FC, Lee JM. Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas. J Thorac Cardiovasc Surg. 2015 Jan;149(1):85-92. doi: 10.1016/j.jtcvs.2014.09.039. Epub 2014 Sep 18.
Yanagawa J, Rusch V. Surgical management of malignant pleural mesothelioma. Thorac Surg Clin. 2013 Feb;23(1):73-87, vi. doi: 10.1016/j.thorsurg.2012.10.002.
Yanagawa J, Rusch VW. Current surgical therapy for stage IIIA (N2) non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2011 Winter;23(4):291-6. doi: 10.1053/j.semtcvs.2011.12.001.